Skip to main content
. Author manuscript; available in PMC: 2022 May 12.
Published in final edited form as: Nat Aging. 2021 Dec 6;1(12):1175–1188. doi: 10.1038/s43587-021-00138-z

Extended Data Fig 5. Longitudinal analyses reveal that sildenafil usage is significantly associated with reduced likelihood of AD in individuals with coronary artery disease (CAD).

Extended Data Fig 5.

Five comparator analyses were conducted including: (a) sildenafil vs. matched non- sildenafil, (b) sildenafil vs. diltiazem (an anti-hypertensive drug), (c) sildenafil vs. losartan (an anti-hypertensive drug candidate in an AD clinical trial [ClinicalTrials.gov Identifier: NCT02913664]), (d) sildenafil vs. glimepiride (an anti-diabetic drug), and (e) sildenafil vs. metformin (an anti-diabetic drug in an AD clinical trial [ClinicalTrials.gov Identifier: NCT00620191]). For each comparator, we estimated the propensity score by using the variables described in Table 1. Then, we estimated the un-stratified Kaplan-Meier curves, conducted propensity score stratified (n strata = 10) log-rank test and Cox model.